Adjuvant BRAF and MEK Inhibition for Melanoma: 'Impressive'

New at ESMO 2017, adjuvant dabrafenib/trametinib in stage III melanoma shows ' impressive ' results in relapse-free survival.

Source: Medscape Oncology - October 31, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts